This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes (DexlonT2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
David Liljenquist, M.D., Rocky Mountain Diabetes and Osteoporosis Center
ClinicalTrials.gov Identifier:
NCT01341067
First received: April 21, 2011
Last updated: April 1, 2014
Last verified: April 2014
April 21, 2011
April 1, 2014
April 2011
December 2011   (Final data collection date for primary outcome measure)
Change in HgbA1c [ Time Frame: Measured at 6 months ]
Change in HgbA1c [ Time Frame: Measured at baseline, 3 months, and 6 months ]
Complete list of historical versions of study NCT01341067 on ClinicalTrials.gov Archive Site
  • Percentage of Time Spent at Glycemic Levels <65 mg/dl [ Time Frame: Measured at baseline and at 6 months ]
  • Change in Percentage of Time Spent at Glycemic Levels >180 mg/dl [ Time Frame: Measured at baseline and 6 months ]
  • Change in Basal Insulin Dose From Baseline Values [ Time Frame: Assessed at baseline and 6 months ]
  • The occurrence of hypoglycemia [ Time Frame: Measured at baseline, 3 months and 6 months. ]
  • Occurence of hyperglycemia [ Time Frame: Measured at baseline, 3 months, and 6 months ]
  • Glucose variability [ Time Frame: Measured at baseline, 3 months, and 6 months ]
  • Percentage of subjects who progressed to basal/bolus treatment due to gathered CGM data [ Time Frame: Assessed at the end of the 6 month trial period ]
  • Change in weight from baseline values [ Time Frame: Measured at baseline and 6 months ]
  • Change in Basal Insulin Dose From Baseline Values [ Time Frame: Assessed at baseline and 6 months ]
  • Confidence of subjects to use the CGM device measured using a certified visual analog scale [ Time Frame: Measured at baseline, 2 weeks, 3 months and 6 months ]
  • Subject satisfaction with their diabetes treatment quantified through the use of the verified ITSQ questionnaire. [ Time Frame: Measured at baseline 3 months, and 6 months ]
  • Subject stress measured using the DDS verified questionnaire [ Time Frame: Measured at baseline, 3 months, and 6 months ]
  • Diabetes symptoms measured using the DSM verified questionnaire [ Time Frame: Measured at baseline, 3 months, and 6 months ]
  • The difference in overall diabetes management between subjects who choose to use the device software versus those who do not. This will be measured using a certified DUVAS and the DDS, DSM, and ITSQ verified questionnaires [ Time Frame: Measured at baseline, 3 months, 6 months ]
Not Provided
Not Provided
 
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
Continuous Glucose Monitoring in Subjects With Type 2 Diabetes
The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has on subjects with type 2 diabetes. It is anticipated that patients using the device will obtain tighter control of their blood sugars resulting in measureable health benefits and improved confidence in their ability to manage their diabetes.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Subjects of all adult ages (18 and older) with type 2 diabetes.
Type 2 Diabetes Mellitus
Not Provided
Basal insulin, approved oral medications
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have been diagnosed with type 2 diabetes mellitus
  • Have an HgbA1c value ≥ 7% and ≤17%.
  • Are on basal insulin, with or without oral agents
  • Are not on basal bolus insulin therapy.
  • Have had no severe hypoglycemic episodes in the 6 months prior to enrollment in the study. Severe hypoglycemia will be defined as any hypoglycemia that is both neurologically impairing and absolutely requires assistance from a third party in the form of carbohydrates, glucagon shots, or attention from a paramedic or other healthcare professional.
  • Have no known allergy to medical tape or sensors.
  • Are capable of and willing to test their blood glucose (BG) on an average of 4 times per day.
  • Are willing to not use Acetaminophen while enrolled in the study.
  • Are willing not to undergo a MRI procedure while wearing the CGM sensor.
  • Are willing and capable of performing self insertions of the device sensor.
  • Women of child bearing potential must be willing to use an approved form of birth control while enrolled in the study.
  • Women of child bearing potential must be willing to perform pregnancy tests monthly while enrolled in the study.
  • Can understand and speak English fluently.

Exclusion Criteria

  • Have been on pump therapy in the 6 months prior to enrollment in the study.
  • Are receiving basal- bolus insulin therapy
  • Are taking any medication that is not approved to be taken with insulin.
  • Are pregnant or have intentions of becoming pregnant during the duration of the study.
  • Have any skin condition that would inhibit the proper wearing of the CGM sensor including severe psoriasis, burns, eczema, scarring, excessive tattoos, etc.
  • Have a hematocrit ≤30% or ≥55%
  • Are currently enrolled in another clinical study (subjects must have ended participation in other studies at least 30 days prior to enrolling in this study.
  • Are employed by any company that manufactures or is developing a CGM device.
  • Are deemed incapable of participating in the study by the Primary Investigator for any reason.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01341067
RMDC-001
Not Provided
Not Provided
Not Provided
Not Provided
David Liljenquist, M.D., Rocky Mountain Diabetes and Osteoporosis Center
Rocky Mountain Diabetes and Osteoporosis Center
Not Provided
Principal Investigator: David R. Liljenquist, MD Rocky Mountain Diabetes and Osteoporosis Center
Rocky Mountain Diabetes and Osteoporosis Center
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP